Provada amb èxit en cabres una nova vacuna contra la tuberculosi

Investigadors del CReSA proven per primer cop i amb èxit una nova vacuna contra la tuberculosi que millora la protecció de l'única vacuna existent en l'actualitat, l'eficàcia de la qual és força limitada. Els estudis s'han realitzat emprant cabres domèstiques, que reprodueixen amb elevada similitud les característiques patològiques i la resposta immunològica a la infecció tuberculosa activa en humans i que, pel fet de ser hostes naturals de la tuberculosi, també permeten estudiar l'ús potencial de la vacuna en animals de granja.Investigadores del CReSA prueban por primera vez y con éxito una nueva vacuna contra la tuberculosis que mejora la protección de la única vacuna existente en la actualidad, cuya eficacia es bastante limitada. Los estudios se han realizado empleando cabras domésticas, que reproducen con elevada similitud las características patológicas y la respuesta inmunológica a la infección tuberculosa activa en humanos y que, por ser huéspedes naturales de la tuberculosis, también permiten estudiar el uso potencial de la vacuna en animales de granja

Una vacuna contra la tuberculosi, provada en cabres

Investigadors del CReSA han dut a terme el primer estudi de vacunació contra la tuberculosi utilitzant com a model experimental la cabra domèstica, que reprodueix amb molta similitud la resposta a la tuberculosi en humans. La vacuna, anomenada AdAg85A, ha estat dissenyada per investigadors de McMaster University (Canadà) per prevenir la tuberculosi en humans, i actualment es troba en fase I d'assajos clínics. De moment, aquest estudi mostra que la inoculació d'aquesta nova vacuna, com a reforç de la vacuna BCG (la única vacuna comercialitzada avui en dia a arreu del món), proporciona major protecció contra la tuberculosi que la vacuna BCG sola

Una vacuna contra la tuberculosi, provada en cabres

Investigadors del CReSA han dut a terme el primer estudi de vacunació contra la tuberculosi utilitzant com a model experimental la cabra domèstica, que reprodueix amb molta similitud la resposta a la tuberculosi en humans. La vacuna, anomenada AdAg85A, ha estat dissenyada per investigadors de McMaster University (Canadà) per prevenir la tuberculosi en humans, i actualment es troba en fase I d'assajos clínics. De moment, aquest estudi mostra que la inoculació d'aquesta nova vacuna, com a reforç de la vacuna BCG (la única vacuna comercialitzada avui en dia a arreu del món), proporciona major protecció contra la tuberculosi que la vacuna BCG sola

Provada amb èxit en cabres una nova vacuna contra la tuberculosi

Investigadors del CReSA proven per primer cop i amb èxit una nova vacuna contra la tuberculosi que millora la protecció de l'única vacuna existent en l'actualitat, l'eficàcia de la qual és força limitada. Els estudis s'han realitzat emprant cabres domèstiques, que reprodueixen amb elevada similitud les característiques patològiques i la resposta immunològica a la infecció tuberculosa activa en humans i que, pel fet de ser hostes naturals de la tuberculosi, també permeten estudiar l'ús potencial de la vacuna en animals de granja.Investigadores del CReSA prueban por primera vez y con éxito una nueva vacuna contra la tuberculosis que mejora la protección de la única vacuna existente en la actualidad, cuya eficacia es bastante limitada. Los estudios se han realizado empleando cabras domésticas, que reproducen con elevada similitud las características patológicas y la respuesta inmunológica a la infección tuberculosa activa en humanos y que, por ser huéspedes naturales de la tuberculosis, también permiten estudiar el uso potencial de la vacuna en animales de granja

Epidemiological Investigation of Bovine Tuberculosis Herd Breakdowns in Spain 2009/2011

We analyzed the most likely cause of 687 bovine tuberculosis (bTB) breakdowns detected in Spain between 2009 and 2011 (i.e., 22% of the total number of breakdowns detected during this period). Seven possible causes were considered: i) residual infection; ii) introduction of infected cattle from other herds; iii) sharing of pastures with infected herds; iv) contiguous spread from infected neighbor herds; v) presence of infected goats in the farm; vi) interaction with wildlife reservoirs and vii) contact with an infected human. For each possible cause a decision tree was developed and key questions were included in each of them. Answers to these key questions lead to different events within each decision tree. In order to assess the likelihood of occurrence of the different events a qualitative risk assessment approach was used. For this purpose, an expert opinion workshop was organized and ordinal values, ranging from 0 to 9 (i.e., null to very high likelihood of occurrence) were assigned. The analysis identified residual infection as the most frequent cause of bTB breakdowns (22.3%; 95%CI: 19.4-25.6), followed by interaction with wildlife reservoirs (13.1%; 95%CI: 10.8-15.8). The introduction of infected cattle, sharing of pastures and contiguous spread from infected neighbour herds were also identified as relevant causes. In 41.6% (95%CI: 38.0-45.4) of the breakdowns the origin of infection remained unknown. Veterinary officers conducting bTB breakdown investigations have to state their opinion about the possible cause of each breakdown. Comparison between the results of our analysis and the opinion from veterinary officers revealed a slight concordance. This slight agreement might reflect a lack of harmonized criteria to assess the most likely cause of bTB breakdowns as well as different perceptions about the importance of the possible causes. This is especially relevant in the case of the role of wildlife reservoirs

A Multi-Antigenic Adenoviral-Vectored Vaccine Improves BCG-Induced Protection of Goats against Pulmonary Tuberculosis Infection and Prevents Disease Progression

The "One world, one health" initiative emphasizes the need for new strategies to control human and animal tuberculosis (TB) based on their shared interface. A good example would be the development of novel universal vaccines against Mycobacterium tuberculosis complex (MTBC) infection. This study uses the goat model, a natural TB host, to assess the protective effectiveness of a new vaccine candidate in combination with Bacillus Calmette-Guerin (BCG) vaccine. Thirty-three goat kids were divided in three groups: Group 1) vaccinated with BCG (week 0), Group 2) vaccinated with BCG and boosted 8 weeks later with a recombinant adenovirus expressing the MTBC antigens Ag85A, TB10.4, TB9.8 and Acr2 (AdTBF), and Group 3) unvaccinated controls. Later on, an endobronchial challenge with a low dose of M. caprae was performed (week 15). After necropsy (week 28), the pulmonary gross pathology was quantified using high resolution Computed Tomography. Small granulomatous pulmonary lesions (< 0.5 cm diameter) were also evaluated through a comprehensive qualitative histopathological analysis. M. caprae CFU were counted from pulmonary lymph nodes. The AdTBF improved the effects of BCG reducing gross lesion volume and bacterial load, as well as increasing weight gain. The number of Ag85A-specific gamma interferon-producing memory T-cells was identified as a predictor of vaccine efficacy. Specific cellular and humoral responses were measured throughout the 13-week post-challenge period, and correlated with the severity of lesions. Unvaccinated goats exhibited the typical pathological features of active TB in humans and domestic ruminants, while vaccinated goats showed only very small lesions. The data presented in this study indicate that multi-antigenic adenoviral vectored vaccines boosts protection conferred by vaccination with BCG

Search for Scalar Diphoton Resonances in the Mass Range 65−60065-600 GeV with the ATLAS Detector in pppp Collision Data at s\sqrt{s} = 8 TeVTeV

A search for scalar particles decaying via narrow resonances into two photons in the mass range 65–600 GeV is performed using $20.3\text{}\text{}{\mathrm{fb}}^{-1}$ of $\sqrt{s}=8\text{}\text{}\mathrm{TeV}$ $pp$ collision data collected with the ATLAS detector at the Large Hadron Collider. The recently discovered Higgs boson is treated as a background. No significant evidence for an additional signal is observed. The results are presented as limits at the 95% confidence level on the production cross section of a scalar boson times branching ratio into two photons, in a fiducial volume where the reconstruction efficiency is approximately independent of the event topology. The upper limits set extend over a considerably wider mass range than previous searches